Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll The biology and treatment of EML4-ALK non-small cell lung cancer Sasaki T; Rodig SJ; Chirieac LR; Janne PAEur J Cancer 2010[Jul]; 46 (10): 1773-80The fusion between echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK) has recently been identified in a subset of non-small cell lung cancers (NSCLCs). EML4-ALK is most often detected in never smokers with lung cancer and has unique pathologic features. EML4-ALK is oncogenic both in vitro and in vivo and ALK kinase inhibitors are quite effective in pre-clinical model systems. More recently ALK inhibitors have entered clinical development and remarkably clinical efficacy has been observed in NSCLC patients harbouring EML4-ALK translocations. This review will focus on the biology, clinical characteristics, diagnosis and treatment of EML4-ALK NSCLC.|Anaplastic Lymphoma Kinase[MESH]|Antineoplastic Agents/therapeutic use[MESH]|Carcinoma, Non-Small-Cell Lung/diagnosis/*genetics/therapy[MESH]|Enzyme Inhibitors/therapeutic use[MESH]|Gene Rearrangement[MESH]|Humans[MESH]|In Situ Hybridization, Fluorescence[MESH]|Lung Neoplasms/diagnosis/*genetics/therapy[MESH]|Mutation[MESH]|Oncogene Proteins, Fusion/*genetics[MESH]|Protein-Tyrosine Kinases/antagonists & inhibitors[MESH]|Receptor Protein-Tyrosine Kinases[MESH]|Reverse Transcriptase Polymerase Chain Reaction[MESH]|Smoking/genetics[MESH]|Translocation, Genetic[MESH] |